Brandes Investment Partners LP Buys 90,285 Shares of Sanofi $SNY

Brandes Investment Partners LP grew its stake in shares of Sanofi (NASDAQ:SNY) by 3.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,913,256 shares of the company’s stock after acquiring an additional 90,285 shares during the period. Brandes Investment Partners LP’s holdings in Sanofi were worth $141,177,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SNY. Brighton Jones LLC grew its stake in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after buying an additional 1,869 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Sanofi by 107.2% during the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after buying an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Sanofi by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after buying an additional 752 shares during the last quarter. Sivia Capital Partners LLC grew its stake in shares of Sanofi by 5.4% during the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after buying an additional 347 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Sanofi by 36.1% during the second quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock worth $159,000 after purchasing an additional 875 shares during the period. Institutional investors own 14.03% of the company’s stock.

Sanofi Price Performance

SNY stock opened at $44.73 on Wednesday. The firm has a market cap of $108.44 billion, a price-to-earnings ratio of 12.49, a PEG ratio of 1.08 and a beta of 0.34. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $42.28 and a 12-month high of $52.68. The company’s fifty day simple moving average is $45.36 and its 200 day simple moving average is $46.64.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were issued a $2.4225 dividend. The ex-dividend date was Monday, May 4th. This is a positive change from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. Sanofi’s dividend payout ratio (DPR) is presently 49.16%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Citigroup reiterated a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Weiss Ratings upgraded shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Morgan Stanley set a $52.00 price target on shares of Sanofi in a report on Friday, May 1st. Finally, Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $51.00.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.